ABVC BioPharma, Inc. revealed on Monday that they've been awarded an Australian patent, which will be valid until 2040. The patent bears the Application Number 2021314052 and pertains to the application of PDC-1421. This is an extract from the herbal plant Radix Polygala, utilised in ABVC BioPharma's product ABV-1504 for the treatment of Major Depressive Disorder, also known as MDD.
The patent was requested from the Australian Patent and Trademark Office and is titled "Polygala Extract for the Treatment of Major Depressive Disorder." Prior to this, the company had procured a U.S patent for the same treatment method, identified as US 11,554,154 B2, which was granted on April 25, 2023.
Uttam Patil, the CEO of ABVC, affirmed that these patents certify ABVC's right to prevent others from using, marketing, or selling PDC-1421 in the United States and Australia, a privilege that is valid up to the year 2040.
